What is Glaukos Corp share price today?

Glaukos Corp (GKOS) share price today is {{live_price}}.

Can Indians buy Glaukos Corp shares?

Yes, Indians can invest in the Glaukos Corp (GKOS) from India. With INDmoney, you can buy Glaukos Corp at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Glaukos Corp at zero transaction cost.

How can I buy Glaukos Corp shares from India?

It is very easy to buy Glaukos Corp from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Glaukos Corp be purchased?

Yes, you can buy fractional shares of Glaukos Corp with INDmoney app.

What are the documents required to start investing in Glaukos Corp stocks?

To start investing in Glaukos Corp, You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Glaukos Corp

Today’s highest price of Glaukos Corp (GKOS) is {{1_rba_end}}. Today’s lowest price of Glaukos Corp (GKOS) is {{1_rba_st}}.

What is today's market capitalisation of Glaukos Corp

Today's market capitalisation of Glaukos Corp GKOS is 2.7B

What is the 52 Week High and Low Range of Glaukos Corp

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Glaukos Corp is down from its 52 Week High?

Glaukos Corp (GKOS) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Glaukos Corp is up from its 52 Week low?

Glaukos Corp (GKOS) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Glaukos Corp?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Glaukos Corp

Mr. Thomas William Burns is the current Chief Executive Officer (CEO) of Glaukos Corp.

Home

US Stocks

Glaukos Corp

Glaukos Corp (GKOS)

$57.02

+1.39

(+2.5%)▲

Market is closed - opens 7 PM, 01 Jun 2023

Insights on Glaukos Corp

Increasing Revenue
Revenue is up for the last 2 quarters, 71.22M → 73.89M (in $), with an average increase of 3.6% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -27.57M → -34.62M (in $), with an average decrease of 12.1% per quarter

Performance

$55.35
$57.16
$57.02
2.93%
Downside
Day's Volatility :3.16%
Upside
0.24%
$39.51
$61.01
$57.02
30.71%
Downside
52 Weeks Volatility :35.24%
Upside
6.54%

Returns

Period	Glaukos Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	17.79%	-0.3%	-6.7%
6 Months	19.45%	-8.8%	-6.2%
1 Year	36.25%	-4.2%	-5.1%
3 Years	37.73%	23.0%	26.9%

Highlights

Market Capitalization	2.7B
Book Value	$10.61
Dividend Share	0.0
Dividend Yield	0.0%
Earnings Per Share (EPS)	-2.82
PEG Ratio	1.64
Wall Street Target Price	58.44

Profit Margin	-48.15%
Operating Margin TTM	-39.82%

Return On Assets TTM	-7.11%
Return On Equity TTM	-25.17%

Revenue TTM	289.1M
Revenue Per Share TTM	6.07
Quarterly Revenue Growth YOY	9.2%
Gross Profit TTM	213.9M
EBITDA	-82.8M
Diluted Eps TTM	-2.82
Quarterly Earnings Growth YOY	18.96

EPS Estimate Current Year	-2.26
EPS Estimate Next Year	-1.85
EPS Estimate Current Quarter	-0.57
EPS Estimate Next Quarter	-0.57

Analyst Recommendation

Buy

61%Buy

38%Hold

0%Sell

Based on 18 Wall street analysts offering stock ratings for Glaukos Corp(by analysts ranked 0 to 5 stars)

Based on 18 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 2.49%

Current $57.02

Target $58.44

Company Financials

	FY17	Y/Y Change
Revenue	159.3M	↑ 39.21%
Net Income	-92.0K	↓ 102.03%
Net Profit Margin	-0.06%	↓ 4.01%

	FY18	Y/Y Change
Revenue	181.3M	↑ 13.83%
Net Income	-13.0M	↑ 13977.17%
Net Profit Margin	-7.14%	↓ 7.08%

	FY19	Y/Y Change
Revenue	237.0M	↑ 30.73%
Net Income	15.4M	↓ 219.1%
Net Profit Margin	6.51%	↑ 13.65%

	FY20	Y/Y Change
Revenue	225.0M	↓ 5.07%
Net Income	-120.3M	↓ 880.26%
Net Profit Margin	-53.5%	↓ 60.01%

	FY21	Y/Y Change
Revenue	294.0M	↑ 30.7%
Net Income	-49.6M	↓ 58.79%
Net Profit Margin	-16.87%	↑ 36.63%

	FY22	Y/Y Change
Revenue	282.9M	↓ 3.79%
Net Income	-99.2M	↑ 100.02%
Net Profit Margin	-35.07%	↓ 18.2%

	Q4 FY21	Q/Q Change
Revenue	73.2M	↓ 1.97%
Net Income	-21.9M	↓ 451.08%
Net Profit Margin	-29.86%	↓ 38.2%

	Q1 FY22	Q/Q Change
Revenue	67.7M	↓ 7.59%
Net Income	5.4M	↓ 124.58%
Net Profit Margin	7.94%	↑ 37.8%

	Q2 FY22	Q/Q Change
Revenue	72.7M	↑ 7.39%
Net Income	-45.5M	↓ 946.87%
Net Profit Margin	-62.65%	↓ 70.59%

	Q3 FY22	Q/Q Change
Revenue	71.3M	↓ 1.95%
Net Income	-27.6M	↓ 39.44%
Net Profit Margin	-38.69%	↑ 23.96%

	Q4 FY22	Q/Q Change
Revenue	71.2M	↓ 0.06%
Net Income	-31.5M	↑ 14.08%
Net Profit Margin	-44.17%	↓ 5.48%

	Q1 FY23	Q/Q Change
Revenue	73.9M	↑ 3.75%
Net Income	-34.6M	↑ 10.06%
Net Profit Margin	-46.86%	↓ 2.69%

	FY17	Y/Y Change
Total Assets	165.8M	↑ 23.42%
Total Liabilities	27.6M	↑ 61.63%

	FY18	Y/Y Change
Total Assets	207.0M	↑ 24.8%
Total Liabilities	33.1M	↑ 19.82%

	FY19	Y/Y Change
Total Assets	818.4M	↑ 295.42%
Total Liabilities	145.1M	↑ 338.32%

	FY20	Y/Y Change
Total Assets	1.0B	↑ 22.86%
Total Liabilities	338.1M	↑ 132.93%

	FY21	Y/Y Change
Total Assets	1.0B	↑ 4.4%
Total Liabilities	462.5M	↑ 36.83%

	FY22	Y/Y Change
Total Assets	1.0B	↓ 4.51%
Total Liabilities	472.4M	↑ 2.13%

	Q4 FY21	Q/Q Change
Total Assets	1.0B	↓ 1.36%
Total Liabilities	462.5M	↓ 0.12%

	Q1 FY22	Q/Q Change
Total Assets	1.1B	↑ 0.23%
Total Liabilities	454.5M	↓ 1.74%

	Q2 FY22	Q/Q Change
Total Assets	1.0B	↓ 1.98%
Total Liabilities	468.8M	↑ 3.15%

	Q3 FY22	Q/Q Change
Total Assets	1.0B	↓ 2.21%
Total Liabilities	459.9M	↓ 1.9%

	Q4 FY22	Q/Q Change
Total Assets	1.0B	↓ 0.6%
Total Liabilities	472.4M	↑ 2.71%

	Q1 FY23	Q/Q Change
Total Assets	972.6M	↓ 2.97%
Total Liabilities	464.1M	↓ 1.76%

	FY17	Y/Y Change
Operating Cash Flow	25.5M	↑ 107.23%
Investing Cash Flow	-11.7M	↓ 55.1%
Financing Cash Flow	4.7M	↓ 384.23%

	FY18	Y/Y Change
Operating Cash Flow	18.9M	↓ 26.05%
Investing Cash Flow	-26.4M	↑ 125.12%
Financing Cash Flow	21.6M	↑ 362.31%

	FY19	Y/Y Change
Operating Cash Flow	-369.0K	↓ 101.96%
Investing Cash Flow	43.4M	↓ 264.49%
Financing Cash Flow	-9.6M	↓ 144.7%

	FY20	Y/Y Change
Operating Cash Flow	-23.0M	↑ 6129.81%
Investing Cash Flow	-205.1M	↓ 572.21%
Financing Cash Flow	262.5M	↓ 2822.05%

	FY21	Y/Y Change
Operating Cash Flow	24.7M	↓ 207.48%
Investing Cash Flow	-58.2M	↓ 71.6%
Financing Cash Flow	39.3M	↓ 85.05%

	FY22	Y/Y Change
Operating Cash Flow	-33.1M	↓ 233.9%
Investing Cash Flow	44.8M	↓ 176.9%
Financing Cash Flow	6.3M	↓ 84.08%

	Q4 FY21	Q/Q Change
Operating Cash Flow	-4.7M	↓ 126.14%
Investing Cash Flow	-8.9M	↓ 65.96%
Financing Cash Flow	1.6M	↓ 58.18%

	Q1 FY22	Q/Q Change
Operating Cash Flow	9.8M	↓ 310.15%
Investing Cash Flow	-5.9M	↓ 33.53%
Financing Cash Flow	1.4M	↓ 12.8%

	Q2 FY22	Q/Q Change
Operating Cash Flow	-12.2M	↓ 224.88%
Investing Cash Flow	9.6M	↓ 263.3%
Financing Cash Flow	106.0K	↓ 92.48%

	Q3 FY22	Q/Q Change
Operating Cash Flow	-26.5M	↑ 117.23%
Investing Cash Flow	24.4M	↑ 153.28%
Financing Cash Flow	4.2M	↑ 3867.92%

	Q4 FY22	Q/Q Change
Operating Cash Flow	-4.1M	↓ 84.4%
Investing Cash Flow	16.7M	↓ 31.72%
Financing Cash Flow	529.0K	↓ 87.42%

	Q1 FY23	Q/Q Change
Operating Cash Flow	-30.8M	↑ 643.81%
Investing Cash Flow	-13.8M	↓ 183.05%
Financing Cash Flow	1.2M	↑ 117.77%

Technicals Summary

Sell

Neutral

Buy

Glaukos Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Glaukos Corp	17.36%	19.45%	36.25%	37.73%	47.29%
Stryker Corporation	-9.47%	16.08%	15.77%	37.64%	56.01%
Boston Scientific Corp.	-4.37%	11.53%	23.12%	34.64%	66.14%
Edwards Lifesciences Corp.	-7.01%	5.39%	-19.28%	9.61%	77.87%
Abbott Laboratories	-8.46%	-5.46%	-13.41%	9.35%	65.3%
Medtronic PLC	-9.02%	4.38%	-17.62%	-15.04%	-4.43%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Glaukos Corp	NA	NA	1.64	-2.26	-0.25	-0.07	0.0	10.61
Stryker Corporation	39.68	39.68	2.85	10.16	0.16	0.06	0.01	44.51
Boston Scientific Corp.	88.03	88.03	2.53	1.95	0.05	0.04	0.0	12.42
Edwards Lifesciences Corp.	33.89	33.89	3.07	2.55	0.25	0.13	0.0	9.87
Abbott Laboratories	31.27	31.27	18.76	4.4	0.16	0.06	0.02	21.28
Medtronic PLC	28.89	28.89	3.04	5.28	0.07	0.04	0.03	38.69

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Glaukos Corp	Buy	$2.7B	47.29%	NA	-48.15%
Stryker Corporation	Buy	$103.5B	56.01%	39.68	13.86%
Boston Scientific Corp.	Buy	$73.4B	66.14%	88.03	6.92%
Edwards Lifesciences Corp.	Buy	$49.7B	77.87%	33.89	27.07%
Abbott Laboratories	Buy	$178.9B	65.3%	31.27	13.98%
Medtronic PLC	Buy	$108.4B	-4.43%	28.89	12.03%

Institutional Holdings

BlackRock Inc
16.19%
Vanguard Group Inc
11.04%
Wellington Management Company LLP
9.12%
Brown Capital Management, LLC
6.04%
Artisan Partners Limited Partnership
3.90%
State Street Corporation
3.64%

Corporate Announcements

Glaukos Corp Earnings
Glaukos Corp’s price-to-earnings ratio stands at None
Read More

Organization	Glaukos Corp
Employees	783
CEO	Mr. Thomas William Burns
Industry	Health Technology

Glaukos Corp (GKOS)

Insights on Glaukos Corp

Increasing Revenue

Decreasing Net Profit